These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 21510726)
21. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798 [TBL] [Abstract][Full Text] [Related]
22. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Chester M; Seedorf G; Tourneux P; Gien J; Tseng N; Grover T; Wright J; Stasch JP; Abman SH Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L755-64. PubMed ID: 21856817 [TBL] [Abstract][Full Text] [Related]
23. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Ghofrani HA; Grimminger F Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121 [TBL] [Abstract][Full Text] [Related]
24. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216 [TBL] [Abstract][Full Text] [Related]
26. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP? Koress C; Swan K; Kadowitz P Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316 [TBL] [Abstract][Full Text] [Related]
27. Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences. Ruiz-Torres MP; Griera M; Chamorro A; Díez-Marqués ML; Rodríguez-Puyol D; Rodríguez-Puyol M Cardiovasc Res; 2009 Apr; 82(1):125-32. PubMed ID: 19126601 [TBL] [Abstract][Full Text] [Related]
28. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920 [TBL] [Abstract][Full Text] [Related]
29. Vasodilator responses to acetylcholine are not mediated by the activation of soluble guanylate cyclase or TRPV4 channels in the rat. Pankey EA; Kassan M; Choi SK; Matrougui K; Nossaman BD; Hyman AL; Kadowitz PJ Am J Physiol Heart Circ Physiol; 2014 Jun; 306(11):H1495-506. PubMed ID: 24658016 [TBL] [Abstract][Full Text] [Related]
30. Relaxant effect of all-trans-retinoic acid via NO-sGC-cGMP pathway and calcium-activated potassium channels in rat mesenteric artery. Wang Y; Han Y; Yang J; Wang Z; Liu L; Wang W; Zhou L; Wang D; Tan X; Fu C; Jose PA; Zeng C Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H51-7. PubMed ID: 23125214 [TBL] [Abstract][Full Text] [Related]
31. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. van Deel ED; Merkus D; van Haperen R; de Waard MC; de Crom R; Duncker DJ Am J Physiol Heart Circ Physiol; 2007 Aug; 293(2):H1144-53. PubMed ID: 17496213 [TBL] [Abstract][Full Text] [Related]
32. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Schäfer A; Fraccarollo D; Werner L; Bauersachs J Pharmacol Res; 2010 Nov; 62(5):432-8. PubMed ID: 20600916 [TBL] [Abstract][Full Text] [Related]
33. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664 [TBL] [Abstract][Full Text] [Related]
34. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874 [TBL] [Abstract][Full Text] [Related]
35. Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern. Michelakis ED Eur Respir J; 2009 Apr; 33(4):717-21. PubMed ID: 19336588 [No Abstract] [Full Text] [Related]
36. New approaches to the treatment of pulmonary hypertension: from bench to bedside. Murthy SN; Nossaman BD; Kadowitz PJ Cardiol Rev; 2010; 18(2):76-84. PubMed ID: 20160533 [TBL] [Abstract][Full Text] [Related]
37. An update on medical therapy for pulmonary arterial hypertension. Wu Y; O'Callaghan DS; Humbert M Curr Hypertens Rep; 2013 Dec; 15(6):614-22. PubMed ID: 24122306 [TBL] [Abstract][Full Text] [Related]